Process Flow Controllers
Medchemexpress LLC ARS-1323 | 1698024-73-5 | 430.84 | 100 MG
ARS-1323 is a potent KRAS G12C inhibitor. It specifically binds to the cysteine residue on the mutant K-Ras protein, locking it in the GDP-bound conformation and effectively blocking K-Ras activation and downstream signaling pathways. This compound is valuable for investigating signal transduction mechanisms and growth characteristics of tumor cells driven by K-Ras G12C.
- KRAS G12C inhibitor
- Specifically binds to the cysteine residue on the mutant K-Ras protein
- Blocks K-Ras activation and downstream signaling pathways
- Useful for investigating signal transduction mechanisms
- Useful for studying growth characteristics of K-Ras G12C driven tumor cells
- Supplied as a white to off-white solid
Medchemexpress LLC ARS-1323 | 1698024-73-5 | 430.84 | 10 MG
ARS-1323 is a KRAS G12C inhibitor that specifically binds to the cysteine residue on the mutant K-Ras protein, locking it in the GDP-bound conformation. This action blocks K-Ras activation and downstream signaling pathways. It can be used to investigate signal transduction mechanisms and growth characteristics of tumor cells driven by K-Ras G12C.
- Targets Ras
- Inhibits GPCR/G Protein and MAPK/ERK pathway
- Powder storage: -20°C for 3 years, 4°C for 2 years
- In solvent storage: -80°C for 2 years, -20°C for 1 year
- Solubility in DMSO: 100 mg/mL (232.10 mM)
- In vivo solubility options available
Medchemexpress LLC ARS-1630 | 1698055-86-5 | 430.84 | 25 MG
ARS-1630 is a novel inhibitor of mutant K-ras G12C, derived from patent WO 2015054572 A1. It is characterized as a less active enantiomer of ARS-1620. This compound targets mutant K-ras G12C, which is considered potentially druggable through allele-specific covalent targeting of Cys-12 near an inducible allosteric switch II pocket. This approach relies on the active cycling of KRAS G12C between its active-GTP and inactive-GDP conformations, as the accessibility of the switch II pocket is limited to the GDP-bound state.
- Specifically inhibits mutant K-ras G12C.
- It is a less active enantiomer of ARS-1620.
- Molecular weight: 430.84.
- Chemical formula: C21H17ClF2N4O2.
- Appears as a white to yellow solid.
Medchemexpress LLC Ars-1630 | 1698055-86-5 | 430.84 | 100 MG
ARS-1630 is a novel inhibitor of mutant K-ras G12C, whose properties are derived from patent WO 2015054572 A1. It is a less active enantiomer of ARS-1620 and is supplied as a white to yellow solid.
- Inhibits mutant K-ras G12C
- Less active enantiomer of ARS-1620
- Available in solid form
- White to yellow appearance
Medchemexpress LLC ARS-1323 | 1698024-73-5 | 430.84 | 25 MG
ARS-1323 is a KRAS G12C inhibitor that specifically binds to the cysteine residue on the mutant K-Ras protein. This action locks K-Ras in its GDP-bound conformation, blocking activation and downstream signaling pathways. It is suitable for investigating signal transduction mechanisms and growth characteristics in tumor cells driven by K-Ras G12C.
- Inhibits KRAS G12C
- Blocks K-Ras activation and downstream signaling
- Investigates signal transduction mechanisms and growth characteristics
- Reduces uptake of [18F]PFPMD by KRAS G12C-mutant H358 NSCLC cells
Medchemexpress LLC ARS-1323 | 1698024-73-5 | 430.84 | 1 ML
ARS-1323 is a KRAS G12C inhibitor that specifically binds to the cysteine residue on the mutant K-Ras protein. This action locks K-Ras in its GDP-bound conformation, effectively blocking its activation and subsequent downstream signaling pathways. It is utilized for investigating signal transduction mechanisms and the growth characteristics of tumor cells driven by K-Ras G12C.
- Specifically binds to the cysteine residue on mutant K-Ras protein
- Blocks K-Ras activation and downstream signaling pathways
- Used to investigate signal transduction mechanisms
- Used for studying growth characteristics of KRAS G12C-driven tumor cells
- High purity of 99.7%
- Available in solid and solution formulations
Medchemexpress LLC ARS-853 | 1629268-00-3 | 98.4% | 432.94 | 100 MG
ARS-853 is a cell-active, selective, covalent KRAS G12C inhibitor that targets mutant KRAS-driven signaling. It works by binding to the GDP-bound oncoprotein, thereby preventing its activation.
- Cell-active, selective, covalent KRAS G12C inhibitor
- Inhibits mutant KRAS-driven signaling
- Binds to GDP-bound oncoprotein
- Prevents KRAS activation
- IC50 of 2.5 μM
- Molecular weight of 432.94
- Purity of 98.4%
- Appearance as a solid
- Color is white to off-white
TARGETMOL CHEMICALS INC ARS-1630 5MG
Also available in 1mg 10mg 25mg 50mg 100mg and bulk. Please contact Fisher for quotes. ARS-1630 is a mutant K-ras G12C inhibitor. It is a less active enantiomer of ARS-1620. purity: 97%
HANNAS PHARMACEUTICAL SUPPLY CO INC 10CC L LOCK SYRNG WITH 41 VNT
NC2607648 10CC L LOCK SYRNG WITH 41 VNT
MICROMERITICS INSTRUMENT CORPORATION SAMPLE CUP 10CC STNLESS STEEL
NC3377211 SAMPLE CUP 10CC STNLESS STEEL
